Home / Basement Membrane Extracts / Cultrex Basement Membrane Extract, Type 3, Pathclear

Cultrex Basement Membrane Extract, Type 3, Pathclear

Catalog #: 3632-010-02
11 Citations 1 Review Datasheet / COA / SDS
Basement Membrane Extract for xenograft and in vivo tumor modeling
Catalog # Availability Size / Price Qty
3632-010-02
Best Seller
Cultrex Basement Membrane Extract, Type 3
1 Image
Product Details
Citations (11)
FAQs
Reviews (1)
Summary Product Datasheets Data Images Background

Cultrex Basement Membrane Extract, Type 3, Pathclear Summary

Specifications

Source
N/A
Endotoxin Level
<8.0 EU per 1 μg of the protein by the LAL method.
Shipping Conditions
The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Storage
Product is stable for a minimum of 3 months from date of shipment when stored at -20 °C in a manual defrost freezer. For optimal stability, store at -80 °C. Avoid freeze-thaw cycles.

Storage Buffer: RPMI1640 medium without phenol red. Sterility Testing: PathClear® - Negative by PCR test for mycoplasma; 17 bacterial and virus strains typically included in mouse antibody production (MAP) testing, plus 13 additional murine infectious agents including LDEV, for a total of 31 organisms and viruses. No bacterial or fungal growth detected after incubation at 37 °C for 14 days following USP sterility testing guidelines.
Applications
Bioactivity

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Cultrex Basement Membrane Extract, Type 3, Pathclear

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

11 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer
    Authors: Yi, Q;Liu, W;Seo, JH;Su, J;Alaoui-Jamali, MA;Luo, J;Lin, R;Wu, JH;
    Molecular cancer therapeutics  2023-05-04
  2. SFyNCS detects oncogenic fusions involving non-coding sequences in cancer
    Authors: X Zhong, J Luan, A Yu, A Lee-Hasset, Y Miao, L Yang
    bioRxiv : the preprint server for biology, 2023-04-06;0(0):.  2023-04-06
  3. Advances in Tumor Organoids for the Evaluation of Drugs: A Bibliographic Review
    Authors: M Londoño-Be, C Castro, A Cañas, I Ortiz, M Osorio
    Pharmaceutics, 2022-12-03;14(12):.  2022-12-03
  4. In vitro and in ovo impact of the ionic dissolution products of boron-doped bioactive silicate glasses on cell viability, osteogenesis and angiogenesis
    Authors: S Decker, M Arango-Osp, F Rehder, A Moghaddam, R Simon, C Merle, T Renkawitz, AR Boccaccini, F Westhauser
    Scientific Reports, 2022-05-20;12(1):8510.  2022-05-20
  5. Three-Dimensional Kidney-on-a-Chip Assessment of Contrast-Induced Kidney Injury: Osmolality and Viscosity
    Authors: K Kim, B Jeong, YM Lee, HE Son, JY Ryu, S Park, JC Jeong, HJ Chin, S Kim
    Micromachines, 2022-04-28;13(5):.  2022-04-28
  6. Early Warnings by Liver Organoids on Short- and Long-Chain PFAS Toxicity
    Authors: S Palazzolo, I Caligiuri, AA Sfriso, M Mauceri, R Rotondo, D Campagnol, V Canzonieri, F Rizzolio
    Toxics, 2022-02-18;10(2):.  2022-02-18
  7. Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer
    Authors: L Yin, Y Zeng, R Zeng, Y Chen, TL Wang, KJ Rodabaugh, F Yu, A Natarajan, AR Karpf, J Dong
    Oncogene, 2021-11-19;0(0):.  2021-11-19
  8. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance
    Authors: CM Yamazaki, A Yamaguchi, Y Anami, W Xiong, Y Otani, J Lee, NT Ueno, N Zhang, Z An, K Tsuchikama
    Nature Communications, 2021-06-10;12(1):3528.  2021-06-10
  9. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
    Authors: R Yang, L Sun, CF Li, YH Wang, J Yao, H Li, M Yan, WC Chang, JM Hsu, JH Cha, JL Hsu, CW Chou, X Sun, Y Deng, CK Chou, D Yu, MC Hung
    Nature Communications, 2021-02-05;12(1):832.  2021-02-05
  10. GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein
    Authors: J Cheng, LR Klei, NE Hubel, M Zhang, R Schairer, LM Maurer, HB Klei, H Kang, VJ Concel, PC Delekta, EV Dang, MA Mintz, M Baens, JG Cyster, N Parameswar, M Thome, PC Lucas, LM McAllister
    J. Clin. Invest., 2020-02-03;130(2):1036-1051.  2020-02-03
  11. Genetic Identification of SEMA3F as an Antilymphangiogenic Metastasis Suppressor Gene in Head and Neck Squamous Carcinoma.
    Authors: Doci C, Mikelis C, Lionakis M, Molinolo A, Gutkind J
    Cancer Res, 2015-05-07;75(14):2937-48.  2015-05-07

FAQs

No product specific FAQs exist for this product, however you may

View all Cell Culture Product FAQs

Reviews for Cultrex Basement Membrane Extract, Type 3, Pathclear

Average Rating: 5 (Based on 1 Review)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Cultrex Basement Membrane Extract, Type 3, Pathclear?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Cultrex Basement Membrane Extract, Type 3, Pathclear
By Anonymous on 07/02/2020